BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Advocacy related to corporate tax policies, including repatriation, "deferral", "check the box", and R&D credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Copyright/Patent/Trademark CPT
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Medicare/Medicaid MMM
Advocacy for appropriate reimbursement terms and payment rates for biologics under the Medicare and Medicaid programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Health Issues HCR
1) Biosimilars, including HR 3590 and HR 4872 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform (HR 3590 and HR 4872) -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.